États-Unis · Plateformes & données · MarketBeat

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Publié par MarketBeat · États-Unis il y a 2 h

Amgen (NASDAQ:AMGN) presented Phase III data at the European Society for Medical Oncology Congress 2026 showing that its DLL3-targeting BiTE therapy IMDELLTRA, when added to…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

À lire aussi

1 Red Flag That Keeps Me From Buying AMD Stock

Yemen’s Houthis renew threat against Riyadh airport as flights set to resume

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

Bank of America resets Tesla forecast as Robotaxi miles double

Amgen's IMDELLTRA Cuts Death Risk 58% in Small-Cell Lung Cancer Study

Partager

À lire aussi

1 Red Flag That Keeps Me From Buying AMD Stock

Yemen’s Houthis renew threat against Riyadh airport as flights set to resume

Musk says Ukraine violated Starlink terms with offensive drone strikes

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Hercules Capital (HTGC) Stock Still Looks Undervalued After A 63% Five Year Run

Bank of America resets Tesla forecast as Robotaxi miles double